Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 17, 2017 - Issue 1
Submit an article Journal homepage
1,667
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Plasma amyloid beta peptides: an Alzheimer’s conundrum or a more accessible Alzheimer’s biomarker?

Anne PoljakCenter for Healthy Brain Ageing (CHeBA), School of Psychiatry, University of NSW, Sydney, Australia;School of Medical Sciences (SOMS), University of NSW, Sydney, Australia;Bioanalytical Mass Spectrometry Facility (BMSF), University of NSW, Sydney, AustraliaCorrespondence[email protected]
View further author information
&
Perminder Singh SachdevCenter for Healthy Brain Ageing (CHeBA), School of Psychiatry, University of NSW, Sydney, Australia;Neuropsychiatric Institute, Prince of Wales Hospital, University of NSW, Sydney, Australia;School of Psychiatry, University of NSW, Sydney, AustraliaView further author information
Pages 3-5 | Received 29 Jun 2016, Accepted 22 Jul 2016, Published online: 31 Jul 2016

References

  • Beach TG, Sue LI, Walker DG, et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer’s disease: implications for amyloid imaging. JAD. 2012;28(4):869–876.
  • Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18(6):794–799.
  • Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. Nat Neurosci. 2015;18(6):800–806.
  • Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
  • Tu S, Okamoto S, Lipton SA, et al. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener. 2014;9:48.
  • Peng Y, Kim MJ, Hullinger R, et al. Improved proteostasis in the secretory pathway rescues Alzheimer’s disease in the mouse. Brain. 2016;139(Pt 3):937–952.
  • Lu T, Aron L, Zullo J, et al. REST and stress resistance in ageing and Alzheimer’s disease. Nature. 2014;507(7493):448–454.
  • Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330(6001):198.
  • Guglielmotto M, Monteleone D, Piras A, et al. Abeta1-42 monomers or oligomers have different effects on autophagy and apoptosis. Autophagy. 2014;10(10):1827–1843.
  • Mufson EJ, Ikonomovic MD, Counts SE, et al. Molecular and cellular pathophysiology of preclinical Alzheimer’s disease. Behav Brain Res. 2016;311:54–69.
  • Quiroz YT, Schultz AP, Chen K, et al. Brain imaging and blood biomarker abnormalities in children with autosomal dominant Alzheimer disease: a cross-sectional study. JAMA Neurol. 2015;72(8):912–919.
  • Tipping KW, van Oosten-Hawle P, Hewitt EW, et al. Amyloid fibres: inert end-stage aggregates or key players in disease? Trends Biochem Sci. 2015;40(12):719–727.
  • Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535–539.
  • Poljak A, Crawford JD, Smythe GA, et al. The relationship between plasma abeta levels, cognitive function and brain volumetrics: Sydney memory and ageing study. Curr Alzheimer Res. 2016;13(3):243–255.
  • Moulin S, Leys D, Schraen-Maschke S, et al. Abeta1-40 and Abeta1-42 plasmatic levels in stroke: influence of pre-existing cognitive status and stroke characteristics. Curr Alzheimer Res. 2015;12:1–9.
  • Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512–519.
  • Izco M, Martínez P, Corrales A, et al. Changes in the brain and plasma Abeta peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuroscience. 2014;263:269–279.
  • Cho SM, Kim HV, Lee S, et al. Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model. Sci Rep. 2014;4:6777.
  • Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2008;105(37):14052–14057.
  • Chouraki V, Beiser A, Younkin L, et al. Plasma amyloid-beta and risk of Alzheimer’s disease in the Framingham heart study. Alzheimers Dement. 2015;11(3):249–257.e1.
  • Kaffashian S, Tzourio C, Soumare A, et al. Association of plasma beta-amyloid with MRI markers of structural brain aging the 3-City Dijon study. Neurobiol Aging. 2015;36(10):2663–2670.
  • Rembach A, Faux NG, Watt AD, et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alzheimers Dement. 2014;10(1):53–61.
  • Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122(4):401–413.
  • Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.